The CJC-1295 and ipamorelin blend costs roughly $150 to $300 a month through telehealth as of October 2026, sold as one combined vial and paid in cash. Neither peptide is FDA-approved, neither is on the FDA’s list of substances pharmacies may compound from bulk, and clinic programs cost more because they bundle visits and labs.
Almost nobody buys CJC-1295 and ipamorelin one at a time. They are marketed, shipped and billed as a single combined blend in one vial — a long-lasting GHRH-analog component paired with a selective ghrelin-receptor secretagogue — which means the “CJC-1295 ipamorelin cost” you keep seeing quoted is the price of the bundle, not the sum of two line items. That bundling is the whole reason the numbers are confusing. Below is how the blend is actually priced in October 2026, what makes one monthly figure twice another, and the question the price tag never answers: whether the evidence justifies the spend at all.
~$150–$300
Typical mail-order telehealth blend, per month
sellers’ public pricing, October 2026
1 vial
How the pair is almost always sold — combined, not separate
$0 covered
Insurance contribution — these are cash-pay only
Why is it a blend price, not two prices?
The two molecules sit at different points on the same growth-hormone axis. CJC-1295 acts as a long-duration GHRH analog; ipamorelin is a selective secretagogue that triggers a GH pulse through the ghrelin receptor with comparatively little spillover onto cortisol or prolactin.[1] Sellers pair them because the two pathways are complementary, and then they reconstitute both into one vial. The practical consequence for cost is that there is rarely a clean “ipamorelin cost” or a standalone “CJC-1295 cost” to quote — you are pricing a fixed-ratio blend, and the ratio, the total milligrams per vial, and how many vials make a month are all set by the seller. Two listings at very different prices can contain effectively the same peptides at different concentrations, which is why per-vial stickers are nearly useless for comparison and per-month is the only honest unit.
How much does the blend cost through telehealth?
The most common way a healthy adult buys this pair is a telehealth prescription filled by a compounding pharmacy and mailed monthly. Here the all-in figure — the blend itself, the asynchronous clinician review, and shipping — generally clusters in the ~$150 to $300 a month band, with the spread driven almost entirely by the wrapper rather than the peptides. Published prices in October 2026 illustrate the spread: Bayan Health lists its CJC/ipamorelin injection at $149 a month (billed monthly over a three-month protocol), Dr. Gillis’ Wellness Center at $185 a month, and Blis MD at $279 a month. A longer prepaid plan (three or six months) lowers the effective monthly rate; a month-to-month order with a first-visit intake fee raises it. None of it is touched by insurance, because a compounded GH-secretagogue blend for “wellness” is not a covered indication — it is cash-pay by definition.
Two things to watch on these listings. First, the “intro” price: a low first-month number that steps up on renewal, exactly as it does across the wider compounded-peptide market — the same pattern we traced in our peptide therapy cost breakdown. Second, blend concentration: a cheaper monthly fee can simply mean a lower-milligram vial that runs out sooner, so the true cost per unit of peptide is higher than it looks.
Route 2 — Clinic and concierge programs: paying for the wrapper
In-person and concierge longevity programs carry the widest variance, because the bill is barely tied to the blend at all. You are paying for an intake visit, a baseline lab panel (often IGF-1 and metabolic markers), injection teaching or in-office administration, and frequently an upsell into adjacent services — a stacked peptide course or an IV add-on. An onboarding package bundling consult, labs and the first cycle can run from several hundred dollars to well over a thousand, with monthly maintenance layered on top. The blend inside that program may be chemically identical to the mail-order version; the premium is the clinical envelope around it. That envelope has real value if you genuinely want monitoring — but it is not buying you a better molecule.
Swipe to see all columns
| How you buy the blend | Typical monthly cost | What the price reflects |
|---|---|---|
| Mail-order telehealth (compounded blend) | ~$150–$300/mo, all-inclusive | The blend + async clinician review + shipping |
| Concierge / in-clinic program | Higher; $1,000+ onboarding, then monthly | Visits, labs, injection teaching, add-on stacks |
| Gray-market “research” blend vial | Lowest sticker per vial | An unverified powder of unconfirmed content |
Can pharmacies legally compound CJC-1295 and ipamorelin?
This is the part of the price that the listings rarely mention. Neither peptide is FDA-approved, and neither is on the list of bulk drug substances that state-licensed (503A) compounding pharmacies may use. Both were previously listed in the FDA’s “Category 2” group of substances that may raise significant safety risks. On the FDA’s current page (content current as of April 22, 2026), CJC-1295 sits under “nominated but withdrawn”: the nominations were withdrawn, so it is no longer in Category 2, but nothing has cleared it for compounding either. Ipamorelin appears twice: its 503A nomination is likewise withdrawn, while it remains in Category 2 for 503B outsourcing facilities. The FDA’s stated concerns are immunogenicity, peptide impurities and, for CJC-1295, reported adverse events including increased heart rate and a systemic vasodilatory reaction.[4] Telehealth sellers still list the blend, so ask any provider which pharmacy compounds it and on what basis.
Route 3 — The gray market: cheapest sticker, unpriced risk
Search the blend by name and you will find sites selling a “CJC-1295/ipamorelin” vial as a powder labeled for laboratory research and explicitly “not” for people. A per-vial sticker that undercuts the telehealth route by half is the whole sales pitch — yet that research-only label is doing quiet work: a research-only blend lives beyond the reach of any pharmacy oversight, and nobody is confirming the vial holds what its label claims, at the stated ratio, free of contaminants. The closest hard data on that hazard comes from the adjacent gray market for GLP-1 drugs, where a market-surveillance study that actually purchased and lab-tested products sold online without a prescription found unregistered sellers, orders that never arrived, and analyzed content diverging from the label — impurities and dose mismatches included.[2] A blend bought the same way inherits that identical hazard: what arrives is not a discounted edition of a verified product but an entirely unverified one.
The part the price tag hides: cost versus evidence
Whatever you pay, the honest organizing question is what the blend is proven to do. Here the answer is narrow: both peptides reliably raise growth hormone and IGF-1 — that is a measured pharmacodynamic effect, including in humans for CJC-1295, and the IGF-1 rise is exactly what is seen when GH secretagogues are given to men in a clinical setting.[3] What does not exist is a body of well-powered human trials showing that the blend builds meaningful muscle, strips fat, or slows aging in healthy adults. So a $150 month and a $300 month are buying the same evidence base — a biomarker story, not an outcome story. That should set the ceiling on what the bundle is worth to you. It is also why the realistic month-by-month timeline for the blend looks so much flatter than the transformation photos used to sell it: the lab value moves, the controlled physique outcome was never measured. We grade the underlying support in the peptide evidence matrix, and the full read on these two specifically lives in the ipamorelin & CJC-1295 evidence review.
How the blend compares on price to its neighbors
For context, the closest legitimate alternatives are priced in the same general territory but bought differently. Compounded sermorelin — a single GHRH analog rather than a two-peptide blend — is the cheapest mainstream telehealth GH-axis option, and the oral secretagogue MK-677 is often pitched as a no-needles substitute. If you are weighing the blend against those, our MK-677 vs. sermorelin comparison and the standalone sermorelin evidence review lay out what each one actually buys, so the decision turns on value rather than on which listing flashes the lowest number.
The honest bottom line
“CJC-1295 ipamorelin cost” is really a question about a blend, and the realistic figure for most people is a compounded telehealth vial at roughly $150–$300 a month, cash only, for two peptides the FDA has not cleared for compounding, with the variation coming from plan length, blend concentration and whether labs and visits are bundled. Concierge programs cost more because you are buying the clinical wrapper; the gray-market powder looks cheapest in the one transaction where the sticker conceals what you are truly paying. The smart move is not to chase the lowest sticker — it is to anchor whatever you pay to a biomarker-deep evidence base, and to compare the legitimate options on care model as well as price in our peptide therapy provider comparison.
